Likarda, a biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics, has received a grant from the Gates Foundation that supports its proprietary Core-Shell Spherification (CSS) system to extend the therapeutic potential of a cost-effective cell-based therapy for infectious diseases. The aim is to develop a formulation that will protect cells modified to release antibodies to treat infectious and chronic disease...